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Randomised trials comparing different
healthcare settings: an exploratory review
of the impact of pre-trial preferences on
participation, and discussion of other
methodological challenges
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Abstract
Background: We recently published a systematic review of different healthcare settings (such as outpatient,
community or home) for administering intravenous chemotherapy, and concluded that performing conventionally
designed randomised trials was difficult. The main problems were achieving adequate trial accrual rates and recruiting
a study population which adequately represented the target population of interest. These issues stemmed from the
fact that potential participants may have had pre-trial perceptions about the trial settings they may be allocated; such
preferences will sometimes be strong enough for patients to decline an invitation to participate in a trial. A patient
preference trial design (in which patients can choose, or be randomised to, an intervention) may have obviated these
recruitment issues, although none of the trials used such a design.
Methods: In order to gain a better understanding of the broader prevalence and extent of these preference issues
(and any other methodological challenges), we undertook an exploratory review of settings trials in any area of healthcare
treatment research. We searched The Cochrane Library and Google Scholar and used snowballing methods to identify
trials comparing different healthcare settings.
Results: Trial accrual was affected by patient preferences for a setting in 15 of the 16 identified studies; birth setting trials
were the most markedly affected, with between 68 % and 85 % of eligible women declining to participate specifically
because of preference for a particular healthcare setting. Recruitment into substance abuse and chemotherapy setting
studies was also notably affected by preferences. Only four trials used a preference design: the proportion of eligible
patients choosing to participate via a preference group ranged from between 33 % and 67 %.
Conclusions: In trials of healthcare settings, accrual may be seriously affected by patient preferences. The use of trial
designs which incorporate a preference component should therefore strongly be considered. When designing such trials,
investigators should consider settings to be complex interventions, which are likely to have linked components which
may be difficult to control for. Careful thought is also needed regarding the choice of comparator settings and the most
appropriate outcome measures to be used.
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Background
Although it may seem self-evident that the physical
environment of healthcare facilities has the potential to
affect health outcomes, only quite recently has there been
wide recognition that well-designed physical settings may
play such an important role. Research evidence in this
area (termed ‘evidence-based design’) has shown that the
design of hospital physical environments may influence a
range of patient health outcomes; staff outcomes; treat-
ment durations; medication requirements; and may
reduce patient, family and staff stress [1].
However, the effect of healthcare settings-the facilities
where health interventions are delivered-may often not
be evaluated. This may, in part, be due to deficiencies in
knowledge and skills about how valid assessments
should be performed, and also what should be evaluated
[2]. In the UK, the NIHR (National Institute for Health
Research) Health Services and Delivery Research
(HS&DR) programme funds research to produce evidence
on the quality, accessibility and organisation of health
services, including evaluations of how the NHS might
improve delivery of services [3]. This area of research
covers the study of the effect of different healthcare treat-
ment settings.
We (MC and AE) were part of a team which published
a HS&DR-funded systematic review which evaluated the
clinical- and cost-effectiveness of different healthcare
settings for administering intravenous chemotherapy.
We studied the effect of home, community, and
outpatient settings on a range of outcomes, which were
mostly patient-reported outcomes such as quality of life,
preference, satisfaction and social functioning. From the
trials identified in the systematic review it was apparent
that performing randomised trials which compared
settings was difficult, particularly in terms of achieving
adequate trial accrual rates and recruiting a study popu-
lation which adequately represented the target popula-
tion of interest [4].
The inherent nature of settings as interventions means
that potential participants may be likely to have pre-trial
perceptions (opinions and likely preferences) about the
trial settings they may be allocated. For example, some
patients may feel anxious about the prospect of receiving
treatment in a hospital setting and would rather be
treated at home, while others may feel the hospital
setting will provide safety and reassurance. These prefer-
ences will sometimes be strong enough for eligible
patients to decline an invitation to participate in a trial.
When performing randomised trials of most kinds of
health intervention-though by no means all [5]- this par-
ticular type of recruitment problem seems unlikely to
result in significant recruitment difficulties. This is
because patients typically have little or no experience
(real or vicarious) on which to form prior perceptions
about at least one of the interventions being evaluated in
the trial. It would therefore not be easy for patients to
relate the potential benefits and harms of all the inter-
ventions due to be studied (and presented in a partici-
pant information sheet) to themselves as individuals. So,
for many types of intervention, the presentation of infor-
mation to prospective participants which explains the
genuine uncertainty about which intervention might be
best, should minimise non-participation rates due to
preferences. However, the accrual data from the trials
included in our chemotherapy setting systematic review
suggested that this may not be the case for setting trials.
Indeed, it is likely that some patients may decide not to
participate before reading a participant information sheet.
In our systematic review of chemotherapy settings we
concluded that the populations in many of the trials
were likely to have been over-represented by hospital-
averse (or home-inclined) patients, and under-represented
by patients who were keen to receive hospital-based (out-
patient) chemotherapy (since the outpatient setting was
the only standard of care available to non-participants in
nearly all of the trials). These self-selection bias and
patient accrual problems appear difficult to overcome by
using conventional randomised trial designs. A design
which might address such problems is the patient
preference trial, of which there are four major types: the
Brewin and Bradley design, the comprehensive cohort, the
Wennberg design and the Rucker design [5]. The compre-
hensive cohort design has been used where it is consid-
ered that patient preferences may introduce bias if
conventional randomisation were to be used [6]. It essen-
tially involves nesting an RCT within a larger observational
cohort of patients: ambivalent patients are randomised, and
patients with preferences receive their preferred interven-
tion. All (consenting) patients are then followed up. Efficacy
estimates would result from the randomised component of
the study and any additional influence of motivational
factors could be studied by comparing patients randomised
to a particular setting with those who chose that same set-
ting [7]. In our systematic review, none of the home
chemotherapy trials incorporated a preference design.
Conventionally-designed randomised trials investigating
the possible effect of a healthcare setting may therefore
give rise to small cohorts of participants with results
which have limited relevance, or generalisibility, to other
populations (i.e. limited external validity), particularly
when the combination of pre-trial preferences and
subjective patient-reported outcomes arises. Furthermore,
as intervention blinding (masking) is not possible in
setting trials, patients randomised to their least-preferred
option (often the standard care setting) may be more likely
to withdraw from the trial, due to the disappointment of
not being allocated the newer (or more appealing) setting.
This kind of patient reaction to treatment allocation is
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often termed resentful demoralisation [8]. In light of the
findings in our systematic review, and in order to gain a
better understanding of the prevalence and extent of these
preference and recruitment issues, we undertook an
exploratory review of settings trials in any area of health-
care treatment research. While examining these trials we
also sought to identify any other setting-related methodo-
logical challenges which may be useful to document to help
inform the planning and design of future trials. The import-
ance of a consideration of the study designs used in this
area of research is particularly relevant, given the call from
NHS England’s Chief Executive for changes in service deliv-
ery to be tested as rigorously as new treatments [9].
Methods
We began by searching The Cochrane Library and Google
Scholar for relevant studies (or reviews which might in-
clude relevant studies). This review was exploratory and
search terms were not pre-defined; searching was an
evolving, iterative process which utilised search terms
such as ‘setting’, ‘home’, ‘community’, ‘home-based’ and ‘in-
patient versus outpatient’ (and vice versa). Snowballing
methods-such as pursuing references of references and
using Google Scholar’s citation search facility-were then
used to identify further studies. This has been shown to be
a particularly efficient use of search time in reviews of
complex evidence [10]. There were no date restrictions.
We included trials where a study objective was to
compare the effects of different healthcare settings (i.e.
the facilities where health interventions are delivered).
For the assessment of the effect of preference on trial
recruitment, randomised trials, or studies which con-
sisted of both a randomised cohort and a cohort of
patients who chose their treatments, were eligible. The
randomisation-only trials had to report the numbers of
eligible patients who opted not to be randomised,
together with reasons for non-participation. Trials which
did not meet these criteria were nevertheless examined
for whether any other setting-related challenges with
trial conduct were evident. For reasons of practicality,
home exercise studies were only considered for cardiac
rehabilitation interventions (since a large number of
trials with interventions which incorporate home exer-
cise exist). Studies which were stopped early due to
recruitment difficulties were eligible.
Results
Effect of preferences on accrual and withdrawals for trials
not offering a preference option
Table 1 lists the healthcare setting studies identified,
with details on how preferences affected patient par-
ticipation. In addition to intravenous chemotherapy,
the clinical areas covered included: opioid depend-
ence, alcohol abuse, cocaine abuse, giving birth, acute
pulmonary embolism, deep vein thrombosis, and car-
diac rehabilitation.
Trial recruitment was affected by patient preferences
for a setting in 15 of the 16 identified studies. Birth set-
ting trials were the most markedly affected, with
between 68 % and 85 % of eligible women declining to
participate specifically because of preference for a par-
ticular setting. Variation was evident across the intraven-
ous chemotherapy trials with between 0 % and 38 % of
eligible patients declining participation due to a setting
preference. Recruitment into substance abuse studies
was also notably affected by setting preferences with 67
% of opioid abusers, 33 % of alcohol abusers, and 33 %
of cocaine abusers opting not to be randomised.
Two trials were stopped early: the OUTREACH trial
was stopped due to poor accrual [11] and the Remonnay
cross-over trial was stopped because 95 % of participants
expressed a preference for home treatment [12]. The
latter trial aimed to recruit 160 patients but was stopped
when only 52 had been recruited; data from 10 patients
who did not participate because they did not want home
treatment were seemingly not considered when inter-
preting the 95 % preference result which triggered the
trial to be stopped. It was also unclear how many
patients were not invited to participate due to lack of
physician consent (which was required as an inclusion
criterion) [12]. Clinician views and preferences certainly
had some impact on accrual in the OUTREACH trial;
the trial authors stated that despite support from clinical
colleagues at the trial design stage, in practice clinicians
were reluctant to refer patients to the trial, with patient
(and staff ) safety being a key concern [11].
In contrast to the data on patient accrual into trials,
the attrition of patients due to setting preferences did
not generally appear to be a problem. Although the
reporting of withdrawals was limited in several trials,
only one trial reported notable numbers of post-
randomisation withdrawals (11 %) for setting reasons [13].
Effect of preferences on accrual and withdrawals for trials
using a preference design
Of the 16 healthcare settings studies identified, only four
used a patient preference design in which patients could
either opt for randomisation, or for their choice of set-
ting (the shaded studies in Table 1) [14–17]. The propor-
tion of eligible patients choosing to participate via a
preference group ranged from between 33 % and 67 %.
Some advantages of this study design are illustrated by
comparing the two cardiac rehabilitation studies in
Table 1: one used conventional randomisation alone [18]
and one used a comprehensive cohort design [16]. Both
trials were performed in England, recruiting around the
same time (between 2002 and 2004 [18], and between
2000 and 2003 [16]). Although both studies randomised
Corbett et al. BMC Health Services Research  (2016) 16:589 Page 3 of 8
a similar proportion of eligible patients (around 40 %),
the comprehensive cohort study recruited a further 45 %
of eligible patients by giving them a choice of setting.
The comprehensive cohort trial recruited 82 % of
eligible patients compared with 43 % in the trial offering
only randomisation. In the latter trial, 28 % of eligible
patients ‘did not wish to take part in a research study’. A
further advantage of the comprehensive cohort design
was the lack of self-selection bias: 7 % of eligible partici-
pants in the randomisation-only trial did not participate
because they wanted the hospital setting, which was
standard care [18]. It is possible that this trial may have
had an inflated proportion of patients (at baseline) who
preferred the home setting (since participating in the
trial was the only way of receiving home treatment).
However, in some areas of clinical research even the use
of a preference trial may still not prevent the recruitment
of a narrower population than desired. This was evidenced
by the trial of rehabilitation in male alcoholics: half the eli-
gible patients ‘refused participation in research’ [15].
Other methodological challenges associated with setting
studies
Our exploratory review also found evidence suggesting
that the following issues should be considered when
planning a setting study.
Choice of outcome measures
The choice of outcome assessment measures to be used
may warrant additional thought (beyond the considerations
Table 1 Effect of preferences on accrual and withdrawal in healthcare setting studies reporting reasons for non-participation
Key:
Grey-shaded studies used a patient preference design, all other studies used randomisation only
Numbers in brackets are % of the potentially eligible patients
aItalicised settings are those available outside of the trial (where information to assess this is reported)
bMay be an underestimate of patients actually eligible as ‘clinicians were reluctant to refer patients to the trial’
cTrials stopped early
dPatients ‘registered in the chemotherapy in the home program’
(X) Cross-over trial
LMWH low-molecular-weight heparin (subcutaneous)
SH standard heparin (intravenous)
Corbett et al. BMC Health Services Research  (2016) 16:589 Page 4 of 8
needed when evaluating conventional healthcare interven-
tions). Some of the outcome measures available to investi-
gators studying healthcare settings may have only been
used previously to evaluate therapeutic interventions, and
may therefore not be sensitive enough to detect the bene-
fits associated with a setting. For example, across the
home chemotherapy trials, the available quality of life
tools tended to focus heavily on physical functioning, ra-
ther than on issues such as the time and energy available
to patients [4].
Other key outcomes which are often evaluated in set-
ting trials are patient satisfaction and patient preference
(i.e. post-trial preference). Assessing satisfaction with
childbirth settings has been reported as being difficult;
satisfaction is determined by a wide variety of factors, so
reducing it to a single ordinal outcome may be meaning-
less [19]. Depending on the study in question, decisions
will therefore need to be made on the trade-off between
the speed and simplicity of using a single-item measure,
and the useful detail provided by more time-consuming
multi-item questionnaires [20]. Where patient preference
is deemed an important outcome, a study design with a
cross-over component should be considered-wherever
feasible-since each patient should (theoretically) experi-
ence both settings. However, cross-over designs should
only really be used for studying patients with relatively
stable disease states. Although preferences were studied in
many of the home chemotherapy cross-over trials, only
one trial investigated strength of preference, which proved
to be an important assessment: around a third of patients
changed their setting preference when they were told their
preferred setting was to involve an extra hour of waiting
[13]. Results from trials which do not consider strength of
preference may therefore have limited use. With these
examples in mind, the collection of qualitative patient
data should strongly be considered to help evaluate
the full range of benefits that different settings may
offer. Qualitative data generated from interviews with
patients and healthcare professionals before and after
a trial can also provide valuable insight regarding bar-
riers to recruitment as well as patients’ healthcare
priorities [11].
Consideration of settings as complex interventions
Complex interventions are characterised according to
several criteria including the number of interacting com-
ponents, the number and difficulty of behaviours re-
quired by those delivering or receiving the intervention,
and the degree of intervention flexibility or tailoring per-
mitted [21]. Organisational and care parameters are very
likely to form important intervention components when
settings are studied. The individual effects of the differ-
ent, yet interacting components of a setting intervention
can be difficult to elucidate. It is therefore likely that
most healthcare settings should be considered complex
interventions when being evaluated in a trial.
This complexity could make evaluation of any ‘setting
effect’ problematic: some investigators may even need to
consider whether attempting to study the setting will be
viable at all. The following example illustrates how
different staff attitudes across settings can have implica-
tions for the conduct and results of a trial. An RCT of
inpatient versus outpatient opioid detoxification was
undertaken because previous trials had methodological
limitations-the key one being that different medication
regimens had been used in each setting, so the oppor-
tunity to study the impact of setting on the likelihood of
success had been missed [22]. The newer trial therefore
aimed to administer the same medical treatment regi-
men, for the same period, in an inpatient and an out-
patient setting. The same clinical protocol was used for
inpatient and outpatient staff, although all staff were
given some flexibility in administering the protocol
(clinicians could increase the period of full-dose lofexidine
by up to 7 days, if clinically indicated). However, at the
end of the trial, the outpatient group had received a sig-
nificantly longer mean medicated period than the in-
patient group (17.9 days versus 11.2 days) which was
linked to the greater flexibility applied by the outpatient
staff. Furthermore, although the protocol required clini-
cians to terminate the detoxification if a patient tested
positive for opioids, cocaine, amphetamine, or unpre-
scribed benzodiazepines, no guidance was provided for
cannabis. This led to an unanticipated difference in practice
with outpatient nurses routinely ignoring positive cannabis
test results, and inpatient staff adopting a strict zero-
tolerance approach to all illicit drugs. Other medication dif-
ferences may have arisen due to the fact that inpatients
were supervised in taking all of their medication whereas
outpatients were not. Although attempts to control for pos-
sible confounders are commendable, this examples suggests
this approach should nevertheless be tempered by an
acceptance that setting interventions have multiple compo-
nents which may be inherently linked and may be difficult
to control for.
Choice of comparator settings
Another issue to consider when designing a setting trial
is how ‘standard’ or ‘usual’ the usual care setting is and
how likely it is to vary across study sites. New healthcare
settings should only be trialled in locations where there
appears to be a need. The relevance of this issue was
exemplified in a trial of intermediate care clinics for
diabetes (ICCD, which are community-based) which
were compared with usual GP care (with referral to sec-
ondary care as required) [23]. This was a cluster rando-
mised trial (randomising 49 GP practices) performed
across three English primary care trusts. The trial had
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recruitment problems, with GPs not referring enough
patients: only 16 % of those eligible were recruited. One
of the reasons for this was the variation in the amount
of referrals made by practices and professionals. Those
making a higher number of referrals tended to view
intermediate care clinics as a higher level of care, while
those making few referrals were usually from practices
with significant diabetes expertise and skills and were
therefore less likely to regard intermediate care as offer-
ing more than could be offered in-house [24].
Discussion
The results from our exploratory review suggest that, in
trials of healthcare settings, accrual may be seriously af-
fected by patient preferences. The use of trial designs
which incorporate a preference component should be
more widely adopted when settings are being trialled,
since results from conventional RCTs may have very
limited applicability to wider patient populations. There
may also be important consequences of the small sample
sizes which often result from conventional RCTs: trials
showing no effect may simply be underpowered to de-
tect effects which might truly exist, or trials with statisti-
cally significant results may in fact be reporting chance
effects. Investigators planning a trial in this area of
research may also need to view the settings as com-
plex interventions which have linked components
which may be difficult to control for. Careful consid-
eration may also be needed regarding decisions on
which comparator settings and outcome assessment
measures might be most appropriate.
The results of a systematic review of preference trials
across a broad range of interventions have indicated that
although preference groups can sometimes yield differ-
ent results to randomised groups, self-selected patients
do often have similar outcomes to randomised patients
[6]. However, those differences in results which were
seen in trials in this review were more frequently found
to be significant in the smaller studies; this finding is im-
portant for our exploratory review since 10 of the 16
studies in Table 1 randomised fewer than 100 patients.
Where findings indicate no differences between rando-
mised and preference cohorts, it should also be consid-
ered that this may be a reflection of patients choosing a
particular treatment for reasons other than believing it
will be the most effective (in terms of improvements in
key trial outcomes). For example, alcohol abusers may
prefer inpatient treatment because they want a safe,
comfortable place to stay, or they may prefer outpatient
treatment as it may not interfere as much with their
daily routines [15]. So, effects on patient-perceived qual-
ity of life (such as improved relationships, self-awareness
and activities of daily living) may be more important to
some patients than the effect on the alcohol and drug
related outcomes important to the trial investigator [25].
In our exploratory review very limited data were avail-
able on why patients had preferences which resulted in
the offer of participation being declined. One identified
study (not tabulated due to the limited detail on reasons
for non-participation) did nevertheless highlight that
travel issues may adversely affect recruitment. It was an
RCT of inpatient versus outpatient chronic pain man-
agement; a post-hoc analysis study, which focussed on
the effects of patient preference, found that the high
rates of refusal to be randomised resulted from the diffi-
culty in traveling from home to hospital. Travel was
more demanding for outpatients (in time and costs) than
for inpatients. Recruitment was also affected by an un-
anticipated predominance of patients referred from distant
locations; patients living further from the treatment unit
were found to be less likely to agree to randomisation [26].
The common theme linking all the methodological is-
sues discussed in our exploratory review is their poten-
tial to affect the external validity of trial results. External
validity, also sometimes referred to as applicability or
generalisability, is the extent to which a result can be
reasonably likely to be replicated when applied to a
definable group of patients in a particular clinical setting.
Lack of external validity is a common criticism by clini-
cians of RCTs, systematic reviews and guidelines. How-
ever, quantification of external validity can be difficult,
requiring clinical rather than statistical expertise and a
detailed understanding of the particular clinical condi-
tion under study and its management in routine clinical
practice [27–29]. Assessments of external validity can
prove particularly difficult when the information needed
is either poorly defined or not reported. The requirement
for providing sufficient details on intervention protocols
may be especially important as complex interventions
may work best if tailored to local circumstances, rather
than being completely standardised; clarity in the report-
ing of how much change or adaptation is permissible is
therefore desirable [21]. Both the complexity of the com-
ponents of setting interventions, and the variability in how
patients are recruited (which ultimately causes variability
in who is recruited) has implications for how practicable it
may be for the trialled interventions to be replicated by
other organisations.
Implications for future studies
It appears likely that most of the RCTs identified in our
study would have benefitted from using a preference
design, although it was unclear why so few of the studies
actually gave patients the option of choosing their set-
ting. Perhaps it was due to a lack of knowledge of the
existence of such designs, or a fear of straying from the
RCT gold standard; the use of less well-known designs
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may lead to difficulties when acquiring funding, or
approvals from ethics or other regulatory committees.
Our hope is that in the future, both setting trialists and
funders might consider different, arguably more appro-
priate, methodological approaches than those offered by
conventional randomised trial designs. Regardless of the
study methods used by investigators, the importance of
performing feasibility studies in this area of research
cannot be over-stated. Furthermore, any subsequent
larger studies should begin with a pilot phase.
In addition to potentially offering improved trial ac-
crual and external validity, patient preference trials may
produce more useful estimates of likely rates of uptake
of the different settings to help inform future service
provision. They may also provide enough data to more
clearly identify any setting-related safety issues (which
appeared to be one of the key clinician concerns about
the implementation of a home or community chemo-
therapy service [11]). Larger studies might also enable
useful assessments to be made of whether setting-related
issues which are important to patients vary according to
patient characteristics. For example, for patients receiv-
ing chemotherapy, waiting times may be more important
for patients who are working, whereas transport issues
may be more important for elderly patients.
Limitations
Being exploratory, our review does have limitations. The
purpose of the study was to identify challenges and
issues which may sometimes be encountered in setting
trials in order that they might be minimised in future
trials. We did not aim to comprehensively and systemat-
ically identify all setting trials, and accept that some rele-
vant studies will not have been identified. Nevertheless,
a strength of this study is that we did consider studies
from any type of clinical setting in order to try and de-
tect a range of methodological issues. Disappointingly,
but perhaps unsurprisingly, our assessment of the im-
pact of preferences on trial recruitment was constrained
by the limited reporting of what happened to patients
before they were randomised. Many trials did not report
adequate details on eligible patients who were not ran-
domised, which limited the number of trials available to
us for studying the recruitment outcomes reported in
Table 1. Although the CONSORT guidelines (for report-
ing parallel-group randomised trials) state that the num-
ber of patients assessed for eligibility should be reported,
it makes little reference of the numbers of eligible
patients who were not randomised, and suggests that
measures of external validity are arguably less important
than the other flow diagram counts [30]. We think that
in this area of study the reporting of data to inform ex-
ternal validity is very important. The lack of such data in
trial reports may not necessarily be due to limited
reporting, but might instead be due to poor trial data
acquisition and collation methods.
Conclusions
In trials of healthcare settings, accrual may be seriously
affected by patient preferences. The use of trial designs
which incorporate a preference component should
therefore strongly be considered. Investigators should
consider the implications of the fact that many settings
are likely to be complex interventions, which have linked
components which may be difficult to control for. When
planning setting trials, careful thought is also needed re-
garding the choice of comparator settings and the most
appropriate outcome assessment measures to be used.
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